Company: INTS
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001567264-25-000103
Chunk: 44

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 44
---
-01 Study (Phase 1/2 Metastatic Cancers)$— $53 $(53)$— $114 $(114)INVINCIBLE-2 Study (Phase 2 Breast)— 12 (12)— 233 (233)INVINCIBLE-3 Study (Phase 3 Sarcoma)883 1,225 (342)3,267 4,613 (1,346)INVINCIBLE-4 Study (Phase 2 Breast)126 108 18 323 424 (101)Other— — — 14 58 (44)Clinical trial expenses1,009 1,398 (389)3,604 5,442 (1,838)Contract manufacturing30 20 10 59 651 (592)Salaries and benefits related costs303 497 (194)925 1,340 (415)Consulting & Other29 49 (20)90 126 (36)Stock-based compensation182 187 (5)605 970 (365)Total research and development expenses$1,553 $2,151 $(598)$5,283 $8,529 $(3,246)

Three Months Ended September 30,Nine Months Ended September 30,20252024Change20252024ChangeGeneral and administrative expenses:Salaries and benefits related costs$225 $325 $(100)$688 $949 $(261)Legal fees130 113 17 371 545 (174)Audit fees72 113 (41)237 286 (49)Consulting145 234 (89)461 573 (112)Insurance185 157 28 501 718 (217)Other134 181 (47)347 523 (176)Stock-based compensation289 296 (7)944 1,259 (315)Total general and administrative expenses$1,180 $1,419 $(239)$3,549 $4,853 $(1,304)

Three Months Ended September 30, 2025 Compared to Three Months Ended September 30, 2024

Research and development expenses during the three months ended September 30, 2025 decreased $0.6 million or 28%, compared to the three months ended September 30, 2024, and were primarily due to the following:

•Salaries and